NTLA
Income statement / Annual
Last year (2023), Intellia Therapeutics, Inc.'s total revenue was $36.28 M,
a decrease of 30.40% from the previous year.
In 2023, Intellia Therapeutics, Inc.'s net income was -$481.19 M.
See Intellia Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$36.28 M
|
$52.12 M
|
$33.05 M
|
$57.99 M
|
$43.10 M
|
$30.43 M
|
$26.12 M
|
$16.48 M
|
$6.04 M
|
$0.00
|
| Cost of Revenue |
$8.98 M |
$7.57 M |
$6.89 M |
$150.41 M |
$108.41 M |
$89.12 M |
$67.65 M |
$31.84 M |
$11.17 M |
$1.66 M |
| Gross Profit |
$27.30 M |
$44.55 M |
$26.16 M |
-$92.41 M |
-$65.31 M |
-$58.68 M |
-$41.53 M |
-$15.36 M |
-$5.13 M |
-$1.66 M |
| Gross Profit Ratio |
0.75 |
0.85 |
0.79 |
-1.59 |
-1.52 |
-1.93 |
-1.59 |
-0.93 |
-0.85 |
0 |
| Research and Development
Expenses |
$435.07 M
|
$419.98 M
|
$229.81 M
|
$150.41 M
|
$108.41 M
|
$89.12 M
|
$67.65 M
|
$31.84 M
|
$11.17 M
|
$10.74 M
|
| General & Administrative
Expenses |
$116.50 M
|
$90.31 M
|
$71.10 M
|
$44.17 M
|
$41.06 M
|
$32.19 M
|
$28.03 M
|
$16.80 M
|
$8.28 M
|
$3.57 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$116.50 M
|
$90.31 M
|
$71.10 M
|
$44.17 M
|
$41.06 M
|
$32.19 M
|
$28.03 M
|
$16.80 M
|
$8.28 M
|
$3.57 M
|
| Other Expenses |
-$435.07 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$551.57 M |
$510.29 M |
$300.90 M |
$194.58 M |
$149.47 M |
$121.30 M |
$95.67 M |
$48.64 M |
$19.45 M |
$12.65 M |
| Cost And Expenses |
$551.57 M |
$510.29 M |
$300.90 M |
$194.58 M |
$149.47 M |
$121.30 M |
$95.67 M |
$48.64 M |
$19.45 M |
$14.31 M |
| Interest Income |
$49.83 M |
$8.54 M |
$1.28 M |
$2.35 M |
$6.84 M |
$5.53 M |
$2.01 M |
$525,000.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$8.54 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$8.98 M
|
$7.57 M
|
$6.89 M
|
$6.31 M
|
$5.59 M
|
$4.46 M
|
$2.99 M
|
$1.10 M
|
$328,000.00
|
$4,500.00
|
| EBITDA |
-$506.22 M
|
-$444.68 M
|
-$267.85 M
|
-$136.58 M
|
-$100.78 M
|
-$90.87 M
|
-$69.56 M
|
-$32.16 M
|
-$13.08 M
|
-$5.22 M
|
| EBITDA Ratio |
-13.95 |
-8.53 |
-8.1 |
-2.36 |
-2.34 |
-2.99 |
-2.66 |
-1.95 |
-2.16 |
0 |
| Operating Income Ratio
|
-14.21
|
-8.79
|
-8.1
|
-2.36
|
-2.47
|
-2.99
|
-2.66
|
-1.95
|
-2.22
|
0
|
| Total Other
Income/Expenses Net |
-$15.73 M
|
-$16.02 M
|
-$42,000.00
|
$2.35 M
|
$6.84 M
|
$5.53 M
|
$2.01 M
|
$525,000.00
|
$0.00
|
-$9.08 M
|
| Income Before Tax |
-$481.19 M |
-$474.19 M |
-$267.89 M |
-$134.23 M |
-$99.53 M |
-$85.34 M |
-$67.54 M |
-$31.63 M |
-$13.41 M |
-$14.31 M |
| Income Before Tax Ratio
|
-13.27
|
-9.1
|
-8.1
|
-2.31
|
-2.31
|
-2.8
|
-2.59
|
-1.92
|
-2.22
|
0
|
| Income Tax Expense |
-$49.73 M |
$16.02 M |
-$8.17 M |
-$8.66 M |
-$6.84 M |
$5.53 M |
-$2.99 M |
-$1.10 M |
-$1.01 M |
$0.00 |
| Net Income |
-$481.19 M |
-$490.21 M |
-$259.72 M |
-$125.57 M |
-$92.70 M |
-$85.34 M |
-$67.54 M |
-$31.63 M |
-$12.40 M |
-$14.31 M |
| Net Income Ratio |
-13.27 |
-9.41 |
-7.86 |
-2.17 |
-2.15 |
-2.8 |
-2.59 |
-1.92 |
-2.05 |
0 |
| EPS |
-5.42 |
-6.37 |
-3.66 |
-2.24 |
-1.96 |
-1.98 |
-1.88 |
-1.42 |
-0.7 |
-29.45 |
| EPS Diluted |
-5.42 |
-6.37 |
-3.66 |
-2.24 |
-1.96 |
-1.98 |
-1.88 |
-1.42 |
-0.7 |
-29.45 |
| Weighted Average Shares
Out |
$88.77 M
|
$76.97 M
|
$70.89 M
|
$55.99 M
|
$47.25 M
|
$43.07 M
|
$36.01 M
|
$22.22 M
|
$17.66 M
|
$485,882.00
|
| Weighted Average Shares
Out Diluted |
$88.77 M
|
$76.97 M
|
$70.89 M
|
$55.99 M
|
$47.25 M
|
$43.07 M
|
$36.01 M
|
$22.22 M
|
$17.66 M
|
$485,882.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
